U.S. markets closed
  • S&P Futures

    3,840.00
    -6.00 (-0.16%)
     
  • Dow Futures

    31,022.00
    -60.00 (-0.19%)
     
  • Nasdaq Futures

    13,367.00
    -28.50 (-0.21%)
     
  • Russell 2000 Futures

    2,137.70
    -0.80 (-0.04%)
     
  • Crude Oil

    52.68
    -0.45 (-0.85%)
     
  • Gold

    1,865.50
    -0.40 (-0.02%)
     
  • Silver

    25.83
    -0.03 (-0.11%)
     
  • EUR/USD

    1.2171
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.1090
    +0.0190 (+1.74%)
     
  • Vix

    21.32
    -0.26 (-1.20%)
     
  • GBP/USD

    1.3724
    -0.0007 (-0.05%)
     
  • USD/JPY

    103.5600
    +0.0550 (+0.05%)
     
  • BTC-USD

    29,661.88
    +129.34 (+0.44%)
     
  • CMC Crypto 200

    584.40
    -95.51 (-14.05%)
     
  • FTSE 100

    6,715.42
    -24.97 (-0.37%)
     
  • Nikkei 225

    28,648.74
    -108.12 (-0.38%)
     

Dynavax to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

·1 min read

EMERYVILLE, Calif., Oct. 22, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report third quarter 2020 financial results on Thursday, November 5, 2020, after the U.S. financial markets close.

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)

Dynavax will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 1475431. A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-november-5-2020-301158328.html

SOURCE Dynavax Technologies